Get 30% off on our Global Market Reports with code ONLINE30 – Hurry, limited time offer!
How Has The Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Growth Evolved From 2024 To 2025, And What’s Ahead?
In the recent past, there has been significant growth in the market size of antineutrophil cytoplasmic antibody (ANCA) associated vasculitis. This growth is set to continue, with the market expected to expand from $0.57 billion in 2024 to $0.63 billion in 2025, indicating a compound annual growth rate (CAGR) of 9.2%. Factors contributing to this growth during the historic period include increased health spending, improved disposable income, a focus on patient-focused care, a rise in the middle-class population, growing use of telemedicine, and an expanding elderly population.
Rapid expansion is anticipated in the antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market in the upcoming years, with predictions of it escalating to $0.88 billion by 2029 at a compound annual growth rate (CAGR) of 9.0%. This anticipated surge over the forecasted period can be credited to factors such as amplified research and clinical trials, escalating research and development pursuits, an increased rate of autoimmune maladies, multiplying instances of immune system malfunctions, and a growing number of corresponding risk factors. The forecast period is expected to see major trends like personalised medical treatments, strategic partnerships, progress in diagnostic tests, increased adoption of telemedicine, and the creation of combination therapies.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23309&type=smp
What are the Fundamental Drivers and Innovations Shaping the Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market?
The escalating occurrence of autoimmune diseases is projected to spur the expansion of the ANCA-associated vasculitis industry. Autoimmune diseases are conditions where the immune system erroneously targets the body’s healthy cells and tissues, misconstruing them as foreign threats such as bacteria or viruses. The increased occurrence of these diseases is linked to environmental factors and lifestyle habits, with a significant association found with exposure to infections and pollutants, leading to disruption in immune tolerance and the onset of abnormal immune responses. Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis has a crucial role in propelling the research and treatments for autoimmune diseases by promoting the production of target-specific immunosuppressive therapies, bolstering early diagnosis methods, and enhancing overall disease control tactics. This consequently results in better patient prognoses and a profound comprehension of immune system regulation. For example, as stated in the Impact of IBD Report 2023 released in September 2023 by the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canada-based institution aiming to enhance the quality of life for patients suffering from Crohn’s disease and ulcerative colitis, the prevalence of inflammatory bowel disease (an autoimmune disease) in Canada in 2023 was 825 in every 100,000 individuals, impacting over 320,000 people. With an estimated yearly increment of 2.44% in prevalence, it is anticipates that by 2035, around 470,000 Canadians, making up 1.1% of the population, would be afflicted with IBD. Hence, the escalating occurrence of autoimmune diseases is set to stimulate the ANCA-associated vasculitis industry.
How Is the Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Segmented?
The antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market covered in this report is segmented –
1) By Type: Granulomatosis With Polyangiitis (GPA Or Wegener’s), Microscopic Polyangiitis (MPA), Eosinophilic Granulomatosis With Polyangiitis (EGPA Or Churg-Strauss), Other Types
2) By Treatment: Immunosuppressants, Corticosteroids, Biologics, Other Treatments
3) By Diagnosis: Blood Tests, Biopsy, Imaging, Other Diagnosis
Subsegments:
1) By Granulomatosis With Polyangiitis (GPA or Wegener’s): Limited Granulomatosis With Polyangiitis, Severe Granulomatosis With Polyangiitis, Refractory Granulomatosis With Polyangiitis
2) By Microscopic Polyangiitis (MPA): Renal Microscopic Polyangiitis, Pulmonary Microscopic Polyangiitis, Neurological Microscopic Polyangiitis
3) By Eosinophilic Granulomatosis With Polyangiitis (EGPA or Churg-Strauss): Cardiac Eosinophilic Granulomatosis With Polyangiitis, Pulmonary Eosinophilic Granulomatosis With Polyangiitis, Neurological Eosinophilic Granulomatosis With Polyangiitis
4) By Other Types: Drug-Induced ANCA-Associated Vasculitis, Infection-Related ANCA-Associated Vasculitis, Overlap Syndrome ANCA-Associated Vasculitis
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=23309&type=smp
Which Regions Are Driving the Next Phase of the Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Growth?
North America was the largest region in the antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Trends Are Shaping the Future of the Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market?
Leading firms in the ANCA-associated vasculitis market are concentrating on creating novel solutions, like targeted treatments, offering a fresh therapeutic alternative for those suffering from a rare and severe condition. Specialized biologic agents are used in the targeted therapy for ANCA-associated vasculitis to selectively restrict the parts of the immune system that cause inflammation and vascular harm, subsequently decreasing disease progression and minimizing toxicity related to treatment. In February 2023, the Switzerland-based Vifor Fresenius Medical Care Renal Pharma (VFMCRP) had approval from The Therapeutic Goods Administration (TGA), an Australian government regulatory agency, for Tavneos (avacopan) to treat anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), in combination with a rituximab or cyclophosphamide-based regimen. The approval of Tavneos marks a crucial milestone as it is the first targeted treatment specifically for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), the main types of ANCA-associated vasculitis. The therapy controls inflammation and disease progression by selectively inhibiting the complement C5a receptor (C5aR1), while minimizing the dependency on high-dose glucocorticoids (steroids), known for severe long-term side effects.
View the full report here:
How Is the Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Defined and What Are Its Core Parameters?
Antineutrophil cytoplasmic antibody (ANCA) associated vasculitis is a rare, autoimmune disorder characterized by inflammation and damage to small and medium-sized blood vessels, primarily affecting organs such as the kidneys, lungs, and respiratory tract, often leading to severe complications if left untreated. This condition is closely linked to nephrology, pulmonology, and rheumatology, requiring multidisciplinary management involving immunosuppressive therapies, corticosteroids, and advanced treatment strategies to prevent organ failure and improve long-term patient outcomes.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23309
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model